Emkay Global Financial Services Limited (BOM:532737)

SpringWorks Therapeutics Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	568.31	324.39	140.76	338.04	111.33
Depreciation & Amortization, Total	105.19	88.63	88.02	71.29	71.53
Gain (Loss) On Sale of Investments	-20.35	-21.34	-4.47	-62.3	-128.88
Stock-Based Compensation	36.56	11.01	-0.9	32.39	20.52
Change in Accounts Receivable	310.24	-198.86	-164.43	-219.21	-134.93
Change in Accounts Payable	-53.69	886.36	-163.98	197.29	-54.7
Change in Other Net Operating Assets	-1,008	-963.54	-494.72	183.92	-391.63
Other Operating Activities	20.18	89.29	-44.2	65.83	43.13
Operating Cash Flow	-20.9	240.46	-634.1	597.42	-442.72
Capital Expenditures	-68.62	-86.47	-78.38	-48.08	-26.83
Investment in Securities	-39.62	-0.96	111.02	-1.89	-10.63
Other Investing Activities	6.61	6.18	16.22	8.95	7.28
Investing Cash Flow	-101.47	-81.13	50.73	-40.21	-30
Short-Term Debt Issued	-	175.85	39.78	9.91	20
Long-Term Debt Issued	460	-	-	-	-
Total Debt Issued	460	175.85	39.78	9.91	20
Short-Term Debt Repaid	-325.54	-	-	-	-
Long-Term Debt Repaid	-36.13	-31.79	-28.09	-33.43	-30.34
Total Debt Repaid	-361.67	-31.79	-28.09	-33.43	-30.34
Net Debt Issued (Repaid)	98.34	144.06	11.7	-23.53	-10.34
Issuance of Common Stock	67.25	4.12	-	1.6	-
Common Dividends Paid	-37.26	-24.67	-30.8	-24.62	-
Other Financing Activities	-19.56	-99.41	-49.9	-26.31	-23.81
Financing Cash Flow	108.77	24.1	-69	-72.85	-34.15
Foreign Exchange Rate Adjustments	0.03	-0.04	-0.11	0.01	-0.09
Net Cash Flow	-13.56	183.39	-652.47	484.37	-506.97
Free Cash Flow	-89.52	153.99	-712.47	549.34	-469.55
Free Cash Flow Margin	-2.53%	4.97%	-33.78%	20.39%	-29.50%
Free Cash Flow Per Share	-3.46	6.05	-28.76	21.08	-19.05
Cash Interest Paid	69.56	49.08	42.8	26.37	23.93
Cash Income Tax Paid	86.66	55.39	67.03	77.83	35.2

Source: S&P Global Market Intelligence. Capital Markets template. Financial Sources.